AAPG Initiated Coverage by Citigroup -- Rated Buy with PT $46

Ascentage Pharma (AAPG) announced that its drug lisaftoclax (APG-2575) received Breakthrough Therapy Designation in China for treating treatment-naïve CLL/SLL. The designation accelerates development and review for the combination therapy. Lisaftoclax is already approved in China for previously treated CLL/SLL patients and is in global Phase III trials.

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss h

BlackRock filed an SEC amendment for the iShares Bitcoin Managed Protection ETF (PBIT), designed to offer partial downside protection and capped upside via options on IBIT or similar assets. The fund will use cash, money-market instruments, and fixed-income securities. The strategy involves three overlapping options tranches, with flexible adjustments based on market conditions. The filing is preliminary, with no shares available until approval.

The Walt Disney Company APAC's president, Luke Kang, is retiring after 16 years. Carol Choi, current executive VP, will succeed him on December 1, 2026. Choi has been with Disney for 20 years and has led content and marketing strategies in the region. Both praised each other's contributions and vision for the future.

Eli Lilly's mirikizumab showed promising results in a phase 3 study for pediatric ulcerative colitis, with 41% achieving clinical remission at week 12, exceeding placebo rates in adults. The study met its primary endpoint of 50% clinical remission at week 52, comparable to adult results. Mirikizumab demonstrated safety and efficacy, with improvements in endoscopic and symptomatic remission. According to researchers, these findings suggest a potential new advanced therapy for pediatric UC.

HUTCHMED (HCM) closed a global license agreement with GSK for HMPL-A830, a cancer drug targeting KRAS-altered tumors. The deal grants GSK worldwide rights (excluding China) and includes a $110M upfront payment, with potential milestone payments up to $1.185B. HUTCHMED will lead Phase I trials, while GSK handles further development and commercialization.